# DFP-10917

Source: https://onco.cc/drugs/dfp-10917/  
OnCo record `dfp-10917` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DFP-10917 is an experimental nucleoside analogue from Delta-Fly Pharma, in phase 3 trials for relapsed or refractory acute myeloid leukaemia; its current status is not stated.

## Summary

DFP-10917 is a nucleoside analogue (continuous intravenous infusion) from Delta-Fly Pharma, with Nippon Shinyaku as licensee. A deoxycytidine-like nucleoside analogue given as a low-dose continuous infusion over 14 days. Its furthest stage is phase 3, for relapsed or refractory acute myeloid leukaemia. ClinicalTrials.gov registers it in 3 studies linked below. The phase 3 trial NCT03926624 in relapsed or refractory AML was TERMINATED: 'The data met the protocol-specified criteria for futility of the investigational treatment' (167 enrolled; completed 7 January 2026). A phase 1/2 with venetoclax (NCT06382168) has registry status UNKNOWN. No company statement on next steps was found. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DFP-10917
- Modality: Nucleoside analogue (continuous intravenous infusion)
- Mechanism: A deoxycytidine-like nucleoside analogue given as a low-dose continuous infusion over 14 days.

## Sources

- Delta-Fly Pharma: delta-flypharma.co.jp: https://www.delta-flypharma.co.jp/en/r-and-d
- Delta-Fly Pharma: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT03926624
- Delta-Fly Pharma: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06382168
- ClinicalTrials.gov: trials of DFP-10917: https://clinicaltrials.gov/search?intr=DFP-10917

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)
- trials: [DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct06382168/), [Phase I/II Study of DFP-10917 in Patients With Acute Leukemia](https://onco.cc/trials/nct01702155/), [Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage](https://onco.cc/trials/nct03926624/)

---
JSON: https://onco.cc/api/v1/entities/dfp-10917.json